First National Bank of Mount Dora Trust Investment Services Trims Stock Position in Pfizer Inc. (NYSE:PFE)

First National Bank of Mount Dora Trust Investment Services lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 8.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,076 shares of the biopharmaceutical company’s stock after selling 3,226 shares during the period. First National Bank of Mount Dora Trust Investment Services’ holdings in Pfizer were worth $878,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. WCG Wealth Advisors LLC grew its stake in Pfizer by 15.3% in the 2nd quarter. WCG Wealth Advisors LLC now owns 32,347 shares of the biopharmaceutical company’s stock worth $905,000 after buying an additional 4,295 shares in the last quarter. XTX Topco Ltd grew its stake in Pfizer by 206.9% in the 2nd quarter. XTX Topco Ltd now owns 73,946 shares of the biopharmaceutical company’s stock worth $2,069,000 after buying an additional 49,851 shares in the last quarter. ProVise Management Group LLC grew its stake in Pfizer by 1.7% in the 2nd quarter. ProVise Management Group LLC now owns 128,926 shares of the biopharmaceutical company’s stock worth $3,607,000 after buying an additional 2,131 shares in the last quarter. Cowa LLC purchased a new position in Pfizer in the 2nd quarter worth approximately $232,000. Finally, Intech Investment Management LLC lifted its holdings in shares of Pfizer by 30.3% in the 2nd quarter. Intech Investment Management LLC now owns 725,663 shares of the biopharmaceutical company’s stock worth $20,304,000 after acquiring an additional 168,724 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.7 %

NYSE:PFE opened at $26.30 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm’s 50-day moving average price is $26.09 and its 200-day moving average price is $28.00. The company has a market capitalization of $149.06 billion, a PE ratio of 35.55, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period last year, the business earned ($0.17) EPS. On average, equities analysts predict that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. Pfizer’s payout ratio is currently 227.03%.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Citigroup assumed coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective for the company. Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Bank of America restated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Finally, Guggenheim lowered their price target on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.